Skip to main content
Top
Published in: Clinical Research in Cardiology 6/2010

Open Access 01-06-2010 | Original Paper

Visualization of transcoronary ablation of septal hypertrophy in patients with hypertrophic obstructive cardiomyopathy: a comparison between cardiac MRI, invasive measurements and echocardiography

Authors: Christian Sohns, Samuel Sossalla, Jan D. Schmitto, Claudius Jacobshagen, Björn W. Raab, Silvia Obenauer, Lars S. Maier

Published in: Clinical Research in Cardiology | Issue 6/2010

Login to get access

Abstract

Objective

Hypertrophic obstructive cardiomyopathy (HOCM) is treated by surgical myectomy or transcoronary ablation of septal hypertrophy (TASH). The aim of this study was to visualize the feasibility, success and short-term results of TASH on the basis of cardiac MRI (CMR) in comparison with cardiac catheterization and echocardiography.

Methods

In this in vivo study, nine patients with HOCM were treated with TASH. Patients were evaluated by transthoracic echocardiography, invasive cardiac angiography and CMR. Follow-up examinations were carried out after 1, 3 and 12 months. MR imaging was performed on a 1.5-T scanner. All images were processed using the semiautomatic Argus software and were evaluated by an attending thoracic radiologist and cardiologist.

Results

The echocardiographic pressure gradient (at rest) was 69.3 ± 15.3 mmHg before and 22.1 ± 5.7 mmHg after TASH (P < 0.01, n = 9). The flux acceleration over the aortic valve examined (V max) was 5.1 ± 0.6 m/s before and 3.4 ± 0.3 m/s after the TASH procedure (P < 0.05). Also, there was a decrease of septum thickness from 22.0 ± 1.2 to 20.2 ± 1.0 mm (P < 0.05) after 6 ± 3 weeks. The invasively assessed pressure gradient at rest was reduced from 63.7 ± 15.2 to 21.2 ± 11.1 mmHg (P < 0.01) and the post-extrasystolic gradient was reduced from 138.9 ± 12.7 to 45.6 ± 16.5 mmHg (P < 0.01). All differences as well as the quantity of injected ethanol were plotted against the size or amount of scar tissue as assessed in the MRI. There was a statistically significant correlation between the post-extrasystolic gradient decrease and the amount of scar tissue (P = 0.03, r 2 = 0.5). In addition, the correlation between the quantity of ethanol and scar tissue area was highly significant (P < 0.01, r 2 = 0.6), whereas the values for the gradient deviation (P = 0.10, r 2 = 0.34), ΔV max (P = 0.12, r 2 = 0.31), as well as the gradient at rest (P = 0.27, r 2 = 0.17) were not significant.

Conclusion

TASH was consistently effective in reducing the gradient in all patients with HOCM. In contrast to the variables investigated by echocardiography, the invasively measured post-extrasystolic gradient correlated much better with the amount of scar tissue as assessed by CMR. We conclude that the optimal modality to visualize the TASH effect seems to be a combination of CMR and the invasive identification of the post-extrasystolic gradient.
Literature
1.
go back to reference Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, Shah PM, Spencer WH, Spirito P, Ten Cate FJ, Wigle ED (2003) ACC/ESC clinical expert consensus document on hypertrophic cardiomyopathy: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 42:1687–1713CrossRefPubMed Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, Shah PM, Spencer WH, Spirito P, Ten Cate FJ, Wigle ED (2003) ACC/ESC clinical expert consensus document on hypertrophic cardiomyopathy: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 42:1687–1713CrossRefPubMed
2.
go back to reference Loogen F, Kuhn H, Gietzen F, Loesse B, Schulte HD, Bircks W (1983) Clinical course and prognosis of patients with typical and atypical hypertrophic obstructive and with hypertrophic nonobstructive cardiomyopathy. Eur Heart J 4:145–153PubMed Loogen F, Kuhn H, Gietzen F, Loesse B, Schulte HD, Bircks W (1983) Clinical course and prognosis of patients with typical and atypical hypertrophic obstructive and with hypertrophic nonobstructive cardiomyopathy. Eur Heart J 4:145–153PubMed
3.
go back to reference Maron BJ, Bonow RO, Cannon RO 3rd, Leon MB, Epstein SE (1987) Hypertrophic cardiomyopathy: interrelations of clinical manifestations, pathophysiology, and therapy (1). N Engl J Med 316:780–789PubMed Maron BJ, Bonow RO, Cannon RO 3rd, Leon MB, Epstein SE (1987) Hypertrophic cardiomyopathy: interrelations of clinical manifestations, pathophysiology, and therapy (1). N Engl J Med 316:780–789PubMed
4.
go back to reference Wigle ED, Rakowski H, Kimball BP, Williams WG (1995) Hypertrophic cardiomyopathy: clinical spectrum and treatment. Circulation 92:1680–1692PubMed Wigle ED, Rakowski H, Kimball BP, Williams WG (1995) Hypertrophic cardiomyopathy: clinical spectrum and treatment. Circulation 92:1680–1692PubMed
5.
go back to reference Spirito P, Seidman CE, McKenna WJ, Maron BJ (1997) The management of hypertrophic cardiomyopathy. N Engl J Med 336:775–785CrossRefPubMed Spirito P, Seidman CE, McKenna WJ, Maron BJ (1997) The management of hypertrophic cardiomyopathy. N Engl J Med 336:775–785CrossRefPubMed
6.
go back to reference Morrow AG, Reitz BA, Epstein SE, Henry WL, Conkle DM, Itsoitz SB, Redwood DR (1975) Operative treatment in hypertrophic subaortic stenosis: techniques, and the results of pre and postoperative assessments in 83 patients. Circulation 52:88–102PubMed Morrow AG, Reitz BA, Epstein SE, Henry WL, Conkle DM, Itsoitz SB, Redwood DR (1975) Operative treatment in hypertrophic subaortic stenosis: techniques, and the results of pre and postoperative assessments in 83 patients. Circulation 52:88–102PubMed
7.
go back to reference Maron BJ, Epstein SE, Morrow AG (1983) Symptomatic status and prognosis of patients after operation for hypertrophic obstructive cardiomyopathy: efficacy of ventricular septal myotomy and myectomy. Eur Heart J 4(suppl F):175–185PubMed Maron BJ, Epstein SE, Morrow AG (1983) Symptomatic status and prognosis of patients after operation for hypertrophic obstructive cardiomyopathy: efficacy of ventricular septal myotomy and myectomy. Eur Heart J 4(suppl F):175–185PubMed
8.
go back to reference Schulte HD, Borisov K, Gams E, Gramsch-Zabel H, Loesse B, Schwartzkopff B (1999) Management of symptomatic hypertrophic obstructive cardiomyopathy: long-term results after surgical therapy. Thorac Cardiovasc Surg 47:213–218CrossRefPubMed Schulte HD, Borisov K, Gams E, Gramsch-Zabel H, Loesse B, Schwartzkopff B (1999) Management of symptomatic hypertrophic obstructive cardiomyopathy: long-term results after surgical therapy. Thorac Cardiovasc Surg 47:213–218CrossRefPubMed
9.
go back to reference Robbins RC, Stinson EB (1996) Long-term results of left ventricular myotomy and myectomy for obstructive hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg 111:586–594CrossRefPubMed Robbins RC, Stinson EB (1996) Long-term results of left ventricular myotomy and myectomy for obstructive hypertrophic cardiomyopathy. J Thorac Cardiovasc Surg 111:586–594CrossRefPubMed
10.
go back to reference Maron BJ, Bonow RO, Cannon RO 3rd, Leon MB, Epstein SE (1987) Hypertrophic cardiomyopathy: interrelations of clinical manifestations, pathophysiology, and therapy (2). N Engl J Med 316:844–852 Maron BJ, Bonow RO, Cannon RO 3rd, Leon MB, Epstein SE (1987) Hypertrophic cardiomyopathy: interrelations of clinical manifestations, pathophysiology, and therapy (2). N Engl J Med 316:844–852
11.
go back to reference Kuhn H, Gietzen F, Ch Leuner, Gerenkamp T (1997) Induction of subaortic septal ischaemia to reduce obstruction in hypertrophic obstructive cardiomyopathy: studies to develop a new catheter-based concept of treatment. Eur Heart J 18:846–851PubMed Kuhn H, Gietzen F, Ch Leuner, Gerenkamp T (1997) Induction of subaortic septal ischaemia to reduce obstruction in hypertrophic obstructive cardiomyopathy: studies to develop a new catheter-based concept of treatment. Eur Heart J 18:846–851PubMed
12.
go back to reference Sigwart U (1995) Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 346:211–214CrossRefPubMed Sigwart U (1995) Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 346:211–214CrossRefPubMed
13.
go back to reference Gietzen FH, ChJ Leuner, Raute-Kreinsen U, Dellmann A, Hegselmann J, Strunk-Mueller C, Kuhn HJ (1999) Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH): catheter interventional treatment for hypertrophic obstructive cardiomyopathy. Eur Heart J 20:1342–1354CrossRefPubMed Gietzen FH, ChJ Leuner, Raute-Kreinsen U, Dellmann A, Hegselmann J, Strunk-Mueller C, Kuhn HJ (1999) Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH): catheter interventional treatment for hypertrophic obstructive cardiomyopathy. Eur Heart J 20:1342–1354CrossRefPubMed
14.
go back to reference Kuhn H, Gietzen FH, Schäfers M, Freick M, Gockel B, Strunk-Müller C, Jachmann E, Schober O (1999) Changes in the left ventricular outflow tract after transcoronary ablation of septal hypertrophy (TASH) for hypertrophic obstructive cardiomyopathy as assessed by transoesophageal echocardiography and by measuring myocardial glucose utilization and perfusion. Eur Heart J 20:1808–1817CrossRefPubMed Kuhn H, Gietzen FH, Schäfers M, Freick M, Gockel B, Strunk-Müller C, Jachmann E, Schober O (1999) Changes in the left ventricular outflow tract after transcoronary ablation of septal hypertrophy (TASH) for hypertrophic obstructive cardiomyopathy as assessed by transoesophageal echocardiography and by measuring myocardial glucose utilization and perfusion. Eur Heart J 20:1808–1817CrossRefPubMed
15.
go back to reference Knight C, Kurbaan AS, Seggewiss H, Henein M, Gunning M, Harrington D, Fassbender D, Gleichmann U, Ul Sigwart (1997) Nonsurgical septal reduction for hypertrophic obstructive cardiomyopathy: outcome in the first series of patients. Circulation 95:2075–2081PubMed Knight C, Kurbaan AS, Seggewiss H, Henein M, Gunning M, Harrington D, Fassbender D, Gleichmann U, Ul Sigwart (1997) Nonsurgical septal reduction for hypertrophic obstructive cardiomyopathy: outcome in the first series of patients. Circulation 95:2075–2081PubMed
16.
go back to reference Faber L, Seggewiss H, Gleichmann U (1998) Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography. Circulation 98:2415–2421PubMed Faber L, Seggewiss H, Gleichmann U (1998) Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography. Circulation 98:2415–2421PubMed
17.
go back to reference Lakkis NM, Nagueh SF, Kleimann NS, Killip D, He ZX, Verani MS, Roberts R, Spencer WH 3rd (1998) Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. Circulation 98:1750–1755PubMed Lakkis NM, Nagueh SF, Kleimann NS, Killip D, He ZX, Verani MS, Roberts R, Spencer WH 3rd (1998) Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. Circulation 98:1750–1755PubMed
18.
go back to reference Boekstegers P, Steinbigler P, Molnar A, Schwaiblmair M, Becker A, Knez A, Haberl R, Steinbeck G (2001) Pressure-guided nonsurgical myocardial reduction induced by small septal infarctions in hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 38:846–853CrossRefPubMed Boekstegers P, Steinbigler P, Molnar A, Schwaiblmair M, Becker A, Knez A, Haberl R, Steinbeck G (2001) Pressure-guided nonsurgical myocardial reduction induced by small septal infarctions in hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 38:846–853CrossRefPubMed
19.
go back to reference Mazur W, Nagueh SF, Lakkis NM, Middelton KJ, Killip D, Roberts R, Spencer WH 3rd (2001) Regression of left ventricular hypertrophy after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation 103:1492–1496PubMed Mazur W, Nagueh SF, Lakkis NM, Middelton KJ, Killip D, Roberts R, Spencer WH 3rd (2001) Regression of left ventricular hypertrophy after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation 103:1492–1496PubMed
20.
go back to reference Nagueh SF, Ommen SR, Lakkis NM, Killip D, Zoghbi WA, Schaff HV, Danielson GK, Quinones MA, Tajik AJ, Spencer WH (2001) Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 38:1701–1706CrossRefPubMed Nagueh SF, Ommen SR, Lakkis NM, Killip D, Zoghbi WA, Schaff HV, Danielson GK, Quinones MA, Tajik AJ, Spencer WH (2001) Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 38:1701–1706CrossRefPubMed
21.
go back to reference Wigle ED, Schwartz L, Woo A, Rakowski H (2001) To ablate or operate? That is the question!. J Am Coll Cardiol 38:1707–1710CrossRefPubMed Wigle ED, Schwartz L, Woo A, Rakowski H (2001) To ablate or operate? That is the question!. J Am Coll Cardiol 38:1707–1710CrossRefPubMed
22.
go back to reference Fananapazir L, McAreavey D (1998) Therapeutic options in patients with obstructive hypertrophic cardiomyopathy and severe drug-refractory symptoms. J Am Coll Cardiol 31:259–264PubMed Fananapazir L, McAreavey D (1998) Therapeutic options in patients with obstructive hypertrophic cardiomyopathy and severe drug-refractory symptoms. J Am Coll Cardiol 31:259–264PubMed
23.
go back to reference Kuhn H, Gietzen FH, Leuner C, Schäfers M, Schober O, Strunk-Müller C, Obergassel L, Freick M, Gockel B, Lieder F, Raute-Kreinsen U (2000) Transcoronary ablation of septal hypertrophy (TASH): a new treatment option for hypertrophic obstructive cardiomyopathy. Z Kardiol 89(4):41–54 Kuhn H, Gietzen FH, Leuner C, Schäfers M, Schober O, Strunk-Müller C, Obergassel L, Freick M, Gockel B, Lieder F, Raute-Kreinsen U (2000) Transcoronary ablation of septal hypertrophy (TASH): a new treatment option for hypertrophic obstructive cardiomyopathy. Z Kardiol 89(4):41–54
24.
go back to reference Spirito P, Maron BJ (1999) Perspectives on the role of new treatment strategies in hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 33:1071–1075CrossRefPubMed Spirito P, Maron BJ (1999) Perspectives on the role of new treatment strategies in hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 33:1071–1075CrossRefPubMed
25.
go back to reference Maron BJ (1999) New interventions for obstructive hypertrophic cardiomyopathy: promise and prudence. Eur Heart J 20:1292–1294CrossRefPubMed Maron BJ (1999) New interventions for obstructive hypertrophic cardiomyopathy: promise and prudence. Eur Heart J 20:1292–1294CrossRefPubMed
26.
go back to reference Braunwald E (2002) Hypertrophic cardiomyopathy: the benefits of a multidisciplinary approach. N Engl J Med 347:1306–1307CrossRefPubMed Braunwald E (2002) Hypertrophic cardiomyopathy: the benefits of a multidisciplinary approach. N Engl J Med 347:1306–1307CrossRefPubMed
27.
go back to reference Kuhn H, Lawrenz LiederF, Leuner C, Strunk-Müller C, Obergassel L, Bartelsmaer M, Stellbrink C (2008) Survival after transcoronary ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy (TASH): a 10 year experience. Clin Res Cardiol 97:234–243CrossRefPubMed Kuhn H, Lawrenz LiederF, Leuner C, Strunk-Müller C, Obergassel L, Bartelsmaer M, Stellbrink C (2008) Survival after transcoronary ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy (TASH): a 10 year experience. Clin Res Cardiol 97:234–243CrossRefPubMed
28.
go back to reference Sahn DJ, De Maria A, Kisslo J, Weymann A (1978) Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 58:1072–1083PubMed Sahn DJ, De Maria A, Kisslo J, Weymann A (1978) Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 58:1072–1083PubMed
29.
go back to reference Gilbert BW, Pollick C, Adelman AG, Wigle ED (1980) Hypertrophic cardiomyopathy: subclassification by M-mode echocardiography. Am J Cardiol 45:861–872CrossRefPubMed Gilbert BW, Pollick C, Adelman AG, Wigle ED (1980) Hypertrophic cardiomyopathy: subclassification by M-mode echocardiography. Am J Cardiol 45:861–872CrossRefPubMed
30.
go back to reference Klues HG, Leuner C, Kuhn H (1992) Left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy: increase in gradient after exercise. J Am Coll Cardiol 19:527–533PubMedCrossRef Klues HG, Leuner C, Kuhn H (1992) Left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy: increase in gradient after exercise. J Am Coll Cardiol 19:527–533PubMedCrossRef
31.
go back to reference Seggewiss H, Faber L, Gleichmann U (1999) Percutaneous transluminal septal ablation in hypertrophic obstruction cardiomyopathy. Thorac Cardiovasc Surg 47:94–100CrossRefPubMed Seggewiss H, Faber L, Gleichmann U (1999) Percutaneous transluminal septal ablation in hypertrophic obstruction cardiomyopathy. Thorac Cardiovasc Surg 47:94–100CrossRefPubMed
32.
go back to reference Alam M, Dokainish H, Lakkis N (2006) Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a systematic review of published studies. J Interven Cardiol 19:319–327CrossRef Alam M, Dokainish H, Lakkis N (2006) Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a systematic review of published studies. J Interven Cardiol 19:319–327CrossRef
33.
go back to reference Seggewiss H, Faber L, Ziemssen P (2000) Age related acute results of percutaneous septal ablation in hypertrophic obstructive cardiomyopathy (abstract). J Am Coll Cardiol 35(Suppl A):188A Seggewiss H, Faber L, Ziemssen P (2000) Age related acute results of percutaneous septal ablation in hypertrophic obstructive cardiomyopathy (abstract). J Am Coll Cardiol 35(Suppl A):188A
34.
go back to reference Sathyamurthy I (2006) Transcoronary ablation of septal hypertrophy (TASH). Indian Heart J 58:371–374PubMed Sathyamurthy I (2006) Transcoronary ablation of septal hypertrophy (TASH). Indian Heart J 58:371–374PubMed
35.
go back to reference Watzinger N, Maier R, Reiter U, Reiter G, Fuernau G, Wonisch M, Fruhwald FM, Schumacher M, Zweiker R, Rienmueller R, Klein W (2005) Clinical applications of cardiovascular magnetic resonance. Curr Pharm Des 11:457–475CrossRefPubMed Watzinger N, Maier R, Reiter U, Reiter G, Fuernau G, Wonisch M, Fruhwald FM, Schumacher M, Zweiker R, Rienmueller R, Klein W (2005) Clinical applications of cardiovascular magnetic resonance. Curr Pharm Des 11:457–475CrossRefPubMed
36.
go back to reference Bernhardt P, Engels T, Knuf B, Strohm O (2006) Cardiac magnetic resonance in outpatients in Germany–indications, complications and protocol suggestions from a high-volume center. Int J Cardiol 28(111):86–91CrossRef Bernhardt P, Engels T, Knuf B, Strohm O (2006) Cardiac magnetic resonance in outpatients in Germany–indications, complications and protocol suggestions from a high-volume center. Int J Cardiol 28(111):86–91CrossRef
37.
go back to reference Schroeder J, Peterschroeder A, Vaske B, Butz T, Barth P, Oldenburg O, Bitter T, Burchert W, Horstkotte D, Langer C (2009) Cardiac volumetry in patients with heart failure and reduced ejection fraction: a comparative study correlating multi-slice computed tomography and magnetic resonance tomography; reasons for intermodal disagreement. Clin Res Cardiol 98:739–747CrossRefPubMed Schroeder J, Peterschroeder A, Vaske B, Butz T, Barth P, Oldenburg O, Bitter T, Burchert W, Horstkotte D, Langer C (2009) Cardiac volumetry in patients with heart failure and reduced ejection fraction: a comparative study correlating multi-slice computed tomography and magnetic resonance tomography; reasons for intermodal disagreement. Clin Res Cardiol 98:739–747CrossRefPubMed
38.
go back to reference Pilz G, Bernhardt P, Harrer E, Klos M, Höfling B (2008) Cardiac magnetic resonance imaging: an essential diagnostic aid in suspected myocardial re-infarction in a 40 year old woman. Clin Res Cardiol 97:280–283CrossRefPubMed Pilz G, Bernhardt P, Harrer E, Klos M, Höfling B (2008) Cardiac magnetic resonance imaging: an essential diagnostic aid in suspected myocardial re-infarction in a 40 year old woman. Clin Res Cardiol 97:280–283CrossRefPubMed
39.
go back to reference Schwab J, Haack G, Sinss D, Bär I, Zahn R (2007) Diagnosis of left ventricular myxoma with cardiac magnetic resonance imaging. Clin Res Cardiol 96:189–190CrossRefPubMed Schwab J, Haack G, Sinss D, Bär I, Zahn R (2007) Diagnosis of left ventricular myxoma with cardiac magnetic resonance imaging. Clin Res Cardiol 96:189–190CrossRefPubMed
40.
go back to reference Altbach MI, Squire SW, Kudithipudi V, Castellano L, Sorrell VL (2007) Cardiac MRI is complementary to echocardiography in the assessment of cardiac masses. Echocardiography 24:286–300CrossRefPubMed Altbach MI, Squire SW, Kudithipudi V, Castellano L, Sorrell VL (2007) Cardiac MRI is complementary to echocardiography in the assessment of cardiac masses. Echocardiography 24:286–300CrossRefPubMed
41.
go back to reference Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, Simonetti O, Klocke FJ, Bonow RO, Judd RM (2000) The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 343:1445–1453CrossRefPubMed Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, Simonetti O, Klocke FJ, Bonow RO, Judd RM (2000) The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 343:1445–1453CrossRefPubMed
42.
go back to reference Nandalur KR, Dwamena BA, Choudhri AF, Nandalur MR, Carlos RC (2007) Diagnostic performance of stress cardiac magnetic resonance imaging in the detection of coronary artery disease: a meta-analysis. J Am Coll Cardiol 50:1343–1353CrossRefPubMed Nandalur KR, Dwamena BA, Choudhri AF, Nandalur MR, Carlos RC (2007) Diagnostic performance of stress cardiac magnetic resonance imaging in the detection of coronary artery disease: a meta-analysis. J Am Coll Cardiol 50:1343–1353CrossRefPubMed
43.
go back to reference Baer FM, Thiessen P, Schneider CA, Voth E, Sechtem U, Schichta H (1998) Dobutamine magnetic resonance imaging predicts contractile recovery of chronically dysfunctional myocardium after successful revascularisation. J Am Coll Cardiol 31:1040–1048CrossRefPubMed Baer FM, Thiessen P, Schneider CA, Voth E, Sechtem U, Schichta H (1998) Dobutamine magnetic resonance imaging predicts contractile recovery of chronically dysfunctional myocardium after successful revascularisation. J Am Coll Cardiol 31:1040–1048CrossRefPubMed
44.
go back to reference Wellhofer E, Olariu A, Klein C, Grafe M, Wahl A, Fleck E, Nagel E (2004) Magnetic resonance low-dose dobutamine test is superior to SCAR quantification for the prediction of functional recovery. Circulation 109:2172–2174CrossRef Wellhofer E, Olariu A, Klein C, Grafe M, Wahl A, Fleck E, Nagel E (2004) Magnetic resonance low-dose dobutamine test is superior to SCAR quantification for the prediction of functional recovery. Circulation 109:2172–2174CrossRef
45.
go back to reference Gotte MJ, van Rossum AC, Twisk JWR, Kuijer JPA, Marcus JT, Visser CA (2001) Quantification of regional contractile function after infarction: strain analysis superior to wall thickening analysis in discriminating infarct from remote myocardium. J Am Coll Cardiol 37:808–817CrossRefPubMed Gotte MJ, van Rossum AC, Twisk JWR, Kuijer JPA, Marcus JT, Visser CA (2001) Quantification of regional contractile function after infarction: strain analysis superior to wall thickening analysis in discriminating infarct from remote myocardium. J Am Coll Cardiol 37:808–817CrossRefPubMed
46.
go back to reference Plein S, Kozerke S, Suder D, Luescher TF, Greenwood JP, Boesiger P, Schwittler J (2008) High spatial resolution myocardial perfusion cardiac magnetic resonance for the detection of coronary artery disease. Eur Heart J (Epub ahead of print) Plein S, Kozerke S, Suder D, Luescher TF, Greenwood JP, Boesiger P, Schwittler J (2008) High spatial resolution myocardial perfusion cardiac magnetic resonance for the detection of coronary artery disease. Eur Heart J (Epub ahead of print)
47.
go back to reference Merkle N, Wöhrle J, Nusser T, Grebe O, Spiess J, Torzewski J, Hombach V (2009) Diagnostic performance of magnetic resonance first pass perfusion imaging is equally potent in female compared to male patients with coronary artery disease. Clin Res Cardiol, Sep 11 (Epub ahead of print) Merkle N, Wöhrle J, Nusser T, Grebe O, Spiess J, Torzewski J, Hombach V (2009) Diagnostic performance of magnetic resonance first pass perfusion imaging is equally potent in female compared to male patients with coronary artery disease. Clin Res Cardiol, Sep 11 (Epub ahead of print)
48.
go back to reference Jensen CJ, Bleckmann D, Eberle HC, Nassenstein K, Schlosser T, Sabin GV, Naber CK, Bruder O (2009) A simple MR algorithm for estimation of myocardial salvage following acute ST segment elevation myocardial infarction. Clin Res Cardiol 98:651–656CrossRefPubMed Jensen CJ, Bleckmann D, Eberle HC, Nassenstein K, Schlosser T, Sabin GV, Naber CK, Bruder O (2009) A simple MR algorithm for estimation of myocardial salvage following acute ST segment elevation myocardial infarction. Clin Res Cardiol 98:651–656CrossRefPubMed
49.
go back to reference Doesch C, Seeger A, Hoevelborn T, Klumpp B, Fenchel M, Kramer U, Schönfisch B, Claussen CD, Gawaz M, Miller S, May AE (2008) Adenosine stress cardiac magnetic resonance imaging for the assessment of ischemic heart disease. Clin Res Cardiol 97:905–912CrossRefPubMed Doesch C, Seeger A, Hoevelborn T, Klumpp B, Fenchel M, Kramer U, Schönfisch B, Claussen CD, Gawaz M, Miller S, May AE (2008) Adenosine stress cardiac magnetic resonance imaging for the assessment of ischemic heart disease. Clin Res Cardiol 97:905–912CrossRefPubMed
50.
go back to reference Veselka J, Duchonová R, Procházková S, Pálenícková J, Sorajja P, Tesar D (2005) Effects of varying ethanol dosing in percutaneous septal ablation for obstructive hypertrophic cardiomyopathy on early hemodynamic changes. Am J Cardiol 95:675–678CrossRefPubMed Veselka J, Duchonová R, Procházková S, Pálenícková J, Sorajja P, Tesar D (2005) Effects of varying ethanol dosing in percutaneous septal ablation for obstructive hypertrophic cardiomyopathy on early hemodynamic changes. Am J Cardiol 95:675–678CrossRefPubMed
51.
go back to reference Faber L, Welge D, Fassbender D, Schmidt HK, Horstkotte D, Seggewiss H (2007) One-year follow-up of percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy in 312 patients: predictors of hemodynamic and clinical response. Clin Res Cardiol 96:864–873CrossRefPubMed Faber L, Welge D, Fassbender D, Schmidt HK, Horstkotte D, Seggewiss H (2007) One-year follow-up of percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy in 312 patients: predictors of hemodynamic and clinical response. Clin Res Cardiol 96:864–873CrossRefPubMed
52.
go back to reference Lawrenz T, Lieder F, Leuner CJ, Obergassel L, Gockel B, Strunk-Mueller C, Kuhn H (2003) What is the correct amount of ethanol in the catheter based treatment for hypertrophic obstructive cardiomyopathy? Eur Heart J 24(Suppl):136CrossRef Lawrenz T, Lieder F, Leuner CJ, Obergassel L, Gockel B, Strunk-Mueller C, Kuhn H (2003) What is the correct amount of ethanol in the catheter based treatment for hypertrophic obstructive cardiomyopathy? Eur Heart J 24(Suppl):136CrossRef
Metadata
Title
Visualization of transcoronary ablation of septal hypertrophy in patients with hypertrophic obstructive cardiomyopathy: a comparison between cardiac MRI, invasive measurements and echocardiography
Authors
Christian Sohns
Samuel Sossalla
Jan D. Schmitto
Claudius Jacobshagen
Björn W. Raab
Silvia Obenauer
Lars S. Maier
Publication date
01-06-2010
Publisher
Springer-Verlag
Published in
Clinical Research in Cardiology / Issue 6/2010
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI
https://doi.org/10.1007/s00392-010-0128-8

Other articles of this Issue 6/2010

Clinical Research in Cardiology 6/2010 Go to the issue